Operating Income

9 Months Ended

Sep. 30, 2021

Other Income and Expenses [Abstract]

Note 8: Operating income

The following table summarizes the operating income during the three and nine months ended September 30, 2021 and 2020:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2021			2020		2021			2020
Research tax credit		1,647			1,815		5,324			7,615
Other operating ( loss ) income		(324	)		2,344		(2,549	)		4,873

Total		1,323			4,158		2,776			12,488

In 2020 and during the first nine months of 2021, the ongoing

COVID-19

pandemic i

pacted the Company’s current clinical trials, including the Phase II clinical trial conducted as part of the development activities pursuant to the collaboration and license agreement with Nestlé Health Science. The Company experienced difficulties in enrolling new patients in this Phase II clinical trial and modified the protocols of the clinical trial. As a result of the accumulation of recruitment delays, the Company expects to incur additional clinical and production costs related to the Phase II clinical trial.

As of September 30, 2021, the Company recorded its collaboration agreement’s revenue based on its updated measurement of progress of the Phase II clinical trial conducted as part of the agreement. The accrual recorded in the amount of the difference between the Company’s current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial has been updated accordingly.